EMEA-001135-PIP01-11 - paediatric investigation plan

teriparatide
PIPHuman

Key facts

Invented name
  • Forsteo
  • Forsteo
Active Substance
teriparatide
Therapeutic area
Endocrinology-Gynaecology-Fertility-Metabolism
Decision number
P/189/2011
PIP number
EMEA-001135-PIP01-11
Pharmaceutical form(s)
  • Solution for injection in pre-filled pen
  • Transdermal system
Condition(s) / indication(s)
  • Treatment of fractures
  • Treatment of osteoporosis
Route(s) of administration
  • Subcutaneous use
  • Transdermal use
Contact for public enquiries

Eli Lilly & Company Limited

E-mail: eu_paediatric@lilly.com 
Tel. +44 (0)1276 483000

Decision type
W: decision granting a waiver in all age groups for all conditions or indications
Decision date

Decision

Share this page